Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-231P is a processed pseudogene derived from the U6 small nuclear RNA (snRNA) gene. U6 snRNA is a key spliceosomal RNA with an essential role in nuclear pre-mRNA splicing, but pseudogenes such as RNU6-231P are non-functional DNA sequences generated by retrotransposition events. These pseudogenes do not produce functional RNA or protein and serve primarily as evolutionary relics or molecular markers of retrotransposition dynamics. RNU6-231P and related U6 snRNA pseudogenes lack biological activity, are not involved in disease processes, and are not considered drug targets. Their main scientific interest is in studies of genomic architecture and evolutionary biology[2][3].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 231, pseudogene (RNU6-231P).